| abstract |
FIELD: organic chemistry, medicine. n SUBSTANCE: invention describes novel spiroazacyclic compounds of the general formula: wherein X means -CH 2 , -CH 2 O, -OCH 2 or oxygen atom (O); Y represents O; Z means -CH or nitrogen atom (N); R 1 means (C 1 -C 6 )-alkyl optionally substituted with morpholinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, 2-oxoimidazolidinyl, imidazolidinyl, 2-oxooxazolidinyl, oxazalidinyl or (C 3 -C 6 )-cycloalkyl, (C 2 -C 8 )-alkyl ester or benzyl ester; m is chosen from group comprising 0 or 1; R 4 means hydrogen atom or benzyl optionally substituted with halogen atom or (C 1 -C 4 )-alkyl; R 5 means hydrogen atom or benzyl optionally substituted with halogen atom, (C 1 -C 4 )-alkyl or (C 1 -C 4 )-alkoxy-group; R 6 means hydrogen atom or benzyl optionally substituted with (C 1 -C 4 )-alkoxy-, cycloalkyl-(C 1 -C 4 -alkoxy)- or halogen-(C 1 -C 4 -alkoxy)-group; R 2 and R 3 mean hydrogen atom and at least two radicals among R 4 , R 5 and R 6 mean optionally substituted benzyl. Also, invention relates to a method for inhibition of activity of serotonin 5-HT 2A receptors, a method for treatment of state mediated by serotonin 5-HT 2A receptors, and using spiroazacyclic compounds proposed. n EFFECT: improved method of treatment, valuable medicinal properties of compounds. n 35 cl, 3 tbl, 2 dwg, 45 ex |